Guideline for the diagnosis and management of hyperuricemia and gout in China(2019)
中国高尿酸血症与痛风诊疗指南(2019)(43283)
The ACE trial: a new perspective on the effect of acarbose on cardiovascular outcomes
ACE研究：阿卡波糖对心血管结局影响的新视角(33723)
Implications and challenges of the ACE trial
ACE研究的启示和挑战(30276)
Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南(27349)
Value of individualized, patient-centered use of short-acting glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of type 2 diabetes mellitus
短效胰升糖素样肽1受体激动剂利司那肽在2型糖尿病个体化治疗中的价值(26191)
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
利司那肽在2型糖尿病个体化治疗中的应用(25655)
The Chinese Journal of Endocrinology and Metabolism (CJEM) was established in July 1985. It is an advanced academic journal sponsored by the Chinese Medical Association reporting recent studies in the field of endocrinology and metabolism in China and around the world.
The target readership of this journal mainly includes endocrinologists and physicians. In the more than 30 years of its development, CJEM has aimed to increase the standard of diagnosis and treatment as well as the clinical management of endocrine and metabolic disorders in China by pursuing advances and targeting hotspots, as well as prudent manuscript solicitation; reporting the latest research outcomes and clinical treatments in endocrinology and metabolism and other relevant fields, as well as basic theoretical research that guides and closely integrates clinical works in endocrinology and metabolism.
